An add-on agent designed to boost drugs that treat age-related macular degeneration failed to show any benefit in two phase 3 ...

Broker Canaccord Genuity says this ASX share potentially 'has no value from here'. Here's what is happening with this ...

The veteran stockpicker told investors the firm would review how its $220 million wager on the biotech went so wrong “to ...

ASX plummets in broad sell-off; gold at new highs; long-time WiseTech chair rejoins board; Todd Sampson exits Qantas; Domain ...

The ranibizumab biosimilar Ongavia exhibited significantly less improvement in visual acuity and retinal thickness compared ...

Opthea said it agreed with the investors in its development funding agreement to end development of sozinibercept in wet AMD, and that the move wouldn't constitute a termination event under the ...

The global prefilled syringes market share is projected to grow from US$ 6.69 Billion in 2022 to US$ 15.0 Billion by 2030, driven by the increasing p ...

The KALAHARI study compared intravitreal injections of THR-149 to Regeneron and Bayer’s anti-VEGF antibody Eylea (aflibercept), a widely-used therapy for DME, in 112 patients for whom the ...

If Bayer's optimistic predictions are proved correct it will be a major boost to the company, which is facing the threat of competition to big-selling pharma products Eylea (aflibercept ...

Cell therapy is emerging as a cutting-edge precision treatment in ophthalmology and is gaining immense popularity worldwide among people affected by degenerative eye diseases. Traditional therapies ...

Alvotech's 427% revenue surge in 2024—fueled by its biosimilar portfolio and global expansion—highlights the booming ...